Steve Schonfeld’s Enanta Pharmaceuticals ENTA Stock Holding History

Steve Schonfeld’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,800	Closed	-$59.6K	–	2166
2025 Q1	$59.6K	Buy	+10,800	New	+$66.7K	﹤0.01%	2063
2022 Q4	–	Sell	-23,415	Closed	-$1.22M	–	2689
2022 Q3	$1.22M	Buy	+23,415	New	+$1.37M	0.01%	1150
2022 Q1	–	Sell	-5,700	Closed	-$426K	–	2675
2021 Q4	$426K	Buy	+5,700	New	+$447K	﹤0.01%	1341
2020 Q2	–	Sell	-4,925	Closed	-$253K	–	1320
2020 Q1	$253K	Buy	+4,925	New	+$262K	0.02%	820
2017 Q4	–	Sell	-6,427	Closed	-$301K	–	765
2017 Q3	$301K	Buy	+6,427	New	+$258K	0.03%	450
2017 Q2	–	Sell	-9,336	Closed	-$288K	–	651
2017 Q1	$288K	Buy	+9,336	New	+$291K	0.03%	479
2016 Q4	–	Sell	-11,376	Closed	-$303K	–	573
2016 Q3	$303K	Sell	11,376 -3,639	-24%	-$84.5K	0.05%	315
2016 Q2	$331K	Buy	15,015 +2,907	+24%	+$76.1K	0.07%	296
2016 Q1	$356K	Buy	+12,108	New	+$337K	0.15%	188

Other funds holding ENTA

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steve Schonfeld's ENTA Position: Q2 2025 in Review

Steve Schonfeld sold out of Enanta Pharmaceuticals (ENTA) in Q2 2025, closing a stake of 10,800 shares — an estimated $59.6K sold.

Steve Schonfeld first reported a position in ENTA in Q1 2016 and held it in 9 quarters. The position peaked at $1.22M in Q3 2022. 108 funds tracked by Wall St. Rank hold ENTA as of Q2 2025.

Steve Schonfeld reported no remaining Enanta Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Steve Schonfeld sold 10,800 Enanta Pharmaceuticals shares in Q2 2025, an estimated $59.6K.
Steve Schonfeld first reported a position in Enanta Pharmaceuticals in Q1 2016 and held it in 9 quarters.
Steve Schonfeld's Enanta Pharmaceuticals position peaked at $1.22M in Q3 2022.
108 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.